FDA recently issued its highly anticipated guidance regarding new dietary ingredient (NDI) notifications, and several aspects have prompted substantial industry objection and concern. Most would agree that the agency thinking, as captured in the guidance document, will impose an increased burden on supplement companies seeking to comply with applicable regulations.
You are here: Home / ALL NEWS / Analytical Testing News & Updates | ADPEN Laboratories / NDA Versus GRAS Ingredients